Effect of STD Management on HIV Transmission — Exam Notes (MD Dermatology)

1. Rationale / Biological Plausibility

• Genital ulcers (syphilis, chancroid, HSV) breach the epithelial barrier → direct portal of entry for virus
• Non-ulcerative STIs (gonorrhea, chlamydia, trichomoniasis, bacterial vaginosis) cause mucosal inflammation → recruitment of CD4+ T cells, macrophages and dendritic (Langerhans) cells to the genital mucosa, providing more target cells for HIV
• Cervicitis/urethritis increases local HIV receptor-bearing cell density

• Genital ulcers and inflamed mucosa recruit HIV-infected CD4+ lymphocytes/macrophages into ulcer secretions and genital secretions → higher local (genital) HIV RNA shedding even if plasma viral load is unchanged
• In chancroid specifically: H. ducreyi ulcers are rich in CD4+ lymphocytes and macrophages, reactivating latent HIV to productive infection with viral excretion into the ulcer — so the ulcer becomes both a portal of entry (for the uninfected) and a portal of exit (for the infected) - Fitzpatrick's Dermatology, p. 875-877

• Risk of HIV acquisition after contact with an HIV+ partner: uncircumcised men with genital ulcer disease 29%, uncircumcised without GUD 6%, circumcised without GUD 2%
• Chancroid transmission probability per single sexual contact ≈ 35%
• Plasma viral load remains the single strongest determinant of transmission risk overall — transmission was rare when plasma HIV RNA was <1700 copies/mL even in presence of genital ulcers (Harrison's Fig. 208-7, Rakai discordant-couple cohort)

2. Classification of STIs relevant to HIV transmission

3. Landmark Community Intervention Trials (the classic exam pair)

Mwanza Trial (Tanzania, Grosskurth et al., Lancet 1995)

• Intervention: Syndromic management of STIs strengthened at existing primary health care units (training health workers, drug supply, referral)
• Result: ~40% reduction in HIV-1 incidence in intervention communities
• Setting: relatively early/emerging HIV epidemic, high background STI prevalence, rural low-frequency-of-care population

Rakai Trial (Uganda, Wawer et al., Lancet 1999)

• Intervention: Mass periodic presumptive treatment of the whole community (all reproductive-age individuals) every 10 months with single-dose antibiotics regardless of symptoms
• Result: No significant reduction in HIV incidence, despite a measurable reduction in some STIs (syphilis)
• Setting: mature/established HIV epidemic, lower prevalence of curable ulcerative STIs (syphilis mainly), HSV-2 already highly prevalent

Why the discordant results? (key exam discussion point)

1. Stage of the HIV epidemic – STI control has greater impact early in an epidemic when HIV transmission is still being "driven" by curable STI cofactors; in a mature epidemic, HIV spreads independent of STIs
2. Type of STI prevalent – Mwanza population had more curable bacterial STIs (syndromic, symptomatic); Rakai population had more HSV-2, which is incurable and was NOT reduced by antibiotic treatment
3. Intervention design – continuous syndromic care at every clinic visit (Mwanza) vs periodic mass treatment every 10 months (Rakai) — gaps between rounds allow STI/HIV transmission to continue
4. Population risk profile – general low-risk rural population vs different sexual network structure

4. The HSV-2 exception (important caveat)

5. Current synthesis (meta-analytic evidence)

• Both ulcerative and non-ulcerative bacterial STIs (gonorrhea, chlamydia, M. genitalium) increase risk of HIV acquisition in heterosexual and MSM populations (PMID: 35034049, PMID: 33783414)
• PLHIV have a high burden of curable STIs, particularly in sub-Saharan Africa, reinforcing the need for integrated STI-HIV services (PMID: 34999605)
• At the individual level, viral load remains dominant; sexual transmission risk becomes very low with an undetectable/low HIV viral load even where STI cofactors exist (PMID: 37490935) — this is the modern (ART/U=U) counterpoint to the older STI-cofactor paradigm

6. Practical/Public Health Application — STI syndromic management as an HIV prevention tool

• WHO syndromic management approach: treat on the basis of a recognizable symptom-complex (urethral discharge, genital ulcer, vaginal discharge, lower abdominal pain) without waiting for lab confirmation — enables immediate, single-visit treatment, especially in low-resource settings
• India (NACO) integrates STI/RTI management as one of the core components of Targeted Interventions (TI) for high-risk groups (sex workers, MSM, IDUs, truckers) alongside condom promotion, ICTC (HIV testing), and behaviour change communication — direct application of the STI-HIV cofactor concept in national HIV control programmes (Park's Textbook of PSM)
• Early diagnosis and treatment of STIs in an HIV-infected person also reduces that person's genital HIV shedding, lowering onward (secondary) transmission risk (Goldman-Cecil Medicine)

7. Summary points to write in exam

1. STIs (especially genital ulcer disease) increase both susceptibility to and infectivity of HIV — biologically plausible, dose-related to number/duration of ulcer episodes
2. Two landmark opposite trials: Mwanza (positive, syndromic mgmt, 40% ↓ HIV) vs Rakai (negative, mass treatment) — difference explained by epidemic stage, STI type (bacterial vs HSV), and intervention frequency
3. STI control works best as HIV prevention early in an epidemic and where curable bacterial STIs (not HSV) predominate
4. Plasma/genital HIV viral load remains the strongest single predictor of transmission — modern ART (U=U) has overtaken STI control as the dominant prevention strategy, but STI/RTI management remains a standard component of combination HIV prevention programmes (syndromic management, targeted interventions)
5. HSV-2 suppressive therapy is the exception that does NOT reduce HIV transmission despite ulcer healing, due to persistent HIV-susceptible inflammatory cells in tissue